ITM, as one of six Belgian test centres recruiting participants, started a phase 3 clinical trial to assess a COVID-19 vaccine developed by Johnson & Johnson. Researchers want to evaluate the level of protection offered by the vaccine and assess the candidate vaccine in various cohorts, including people with chronic diseases. Vaccines are a priority for ITM. Our expertise covers the different aspects of the vaccination process, from inoculations in the travel clinic to clinical studies and scientific research into microbiological, immunological and anthropological issues.